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Abstract
Background: Empirical antibiotic coverage for atypical pathogens in community-acquired pneumonia (CAP) has
long been debated, mainly because of a lack of epidemiological data. We aimed to assess both testing for atypical
pathogens and their prevalence in hospitalized patients with CAP worldwide, especially in relation with disease
severity.
Methods: A secondary analysis of the GLIMP database, an international, multicentre, point-prevalence study of
adult patients admitted for CAP in 222 hospitals across 6 continents in 2015, was performed. The study evaluated
frequency of testing for atypical pathogens, including L. pneumophila, M. pneumoniae, C. pneumoniae, and their
prevalence. Risk factors for testing and prevalence for atypical pathogens were assessed through univariate analysis.
Results: Among 3702 CAP patients 1250 (33.8%) underwent at least one test for atypical pathogens. Testing varies
greatly among countries and its frequency was higher in Europe than elsewhere (46.0% vs. 12.7%, respectively, p < 0.
0001). Detection of L. pneumophila urinary antigen was the most common test performed worldwide (32.0%). Patients
with severe CAP were less likely to be tested for both atypical pathogens considered together (30.5% vs. 35.0%, p = 0.009)
and specifically for legionellosis (28.3% vs. 33.5%, p = 0.003) than the rest of the population. Similarly, L. pneumophila
testing was lower in ICU patients. At least one atypical pathogen was isolated in 62 patients (4.7%), including M.
pneumoniae (26/251 patients, 10.3%), L. pneumophila (30/1186 patients, 2.5%), and C. pneumoniae (8/228 patients, 3.5%).
Patients with CAP due to atypical pathogens were significantly younger, showed less cardiovascular, renal, and metabolic
comorbidities in comparison to adult patients hospitalized due to non-atypical pathogen CAP.
Conclusions: Testing for atypical pathogens in patients admitted for CAP in poorly standardized in real life and does not
mirror atypical prevalence in different settings. Further evidence on the impact of atypical pathogens, expecially in the
low-income countries, is needed to guidelines implementation.
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Background
Community-acquired pneumonia (CAP) is a leading cause
of hospitalization and death worldwide [1]. The annual esti-
mated CAP burden in the Unites States of America (USA)
accounts for more than 1.5 million adult hospitalizations
and one third of hospitalized patients die within 1 year [2].
The assessment of the epidemiology of CAP-related patho-
gens is crucial to target appropriate empiric therapy in
order to improve patients’ outcomes. The empirical cover-
age for atypical pathogens, including Mycoplasma pneumo-
niae, Chlamydia pneumoniae, and Legionella pneumophila,
is still a matter of debate [3].
Several Authors reported on an increased trend of
atypical pathogens over the last 15 years, with prevalences
ranging from 6 to 40% in both Europe and USA [4]. One
study performed in China showed atypical pathogens as
the most frequent cause of CAP with incidence rates far
exceeding Streptococcus pneumoniae [5]. Other studies
described similar prevalences of atypical pathogens [6].
Epidemiological data are mainly based on retrospective
studies or secondary analyses of local or national datasets
with key design limitations, such as: 1) cultures for atypicals
are rarely performed and a standardized diagnostic approach
has not been adopted; 2) serology for atypical pathogens
could be prescribed for epidemiological studies according to
international guidelines and an all-encompassing microbio-
logical work-up should be carried out only for hospitalized
patients with severe CAP [1, 7]; 3) information on testing
frequency of atypical pathogens and which population sub-
groups are more likely to be investigated are missing. Finally,
the only published description on atypical pathogens in
CAP is a secondary analysis of a retrospective database [6].
The aim of this study was to provide a real-life descrip-
tion of both testing frequency and prevalence of atypical
pathogens in hospitalized patients with CAP worldwide,
along with the evaluation of predisposing conditions for
testing and risk factors for CAP caused by atypical
pathogens.
Methods
Study design and population
The present study is based on a secondary analysis of the
Global Initiative for MRSA Pneumonia (GLIMP) inter-
national database [8]. This project was not funded and re-
lied upon voluntary site and investigator participation.
The GLIMP methodology has been already published
elsewhere [8]. The coordinating center (University of
Texas Health at San Antonio –UT Health-, Texas, USA)
received project approval by the Institutional Review
Board (IRB# HSC20150184E). All participating centers
followed their local law and regulations. Study participants
were enrolled on a single day in the months of March,
April, May, and June in 2015.
All adults (> 18 years old) hospitalized with CAP were
screened for study selection. CAP was defined by the
evidence of new radiological pulmonary infiltrates during
the first 48 h of hospitalization and by ≥1 of the following
criteria: 1) new or increased cough with/without sputum
production and/or purulent respiratory secretions; 2) fever
(documented rectal or oral temperature ≥ 37.8 °C) or
hypothermia (documented rectal or oral temperature < 36 °
C); 3) systemic inflammation (e.g., white blood cell count >
10,000/cm3 or < 4000/cm3, C-reactive protein or procalcito-
nin values above the local upper limit of normality). Pa-
tients hospitalized with a diagnosis of hospital-acquired
and/or ventilator-associated pneumonia were excluded.
Patients without any bacterial tests for atypical pathogens
collected within 24 h after hospital admission were also
excluded.
Data collection and microbiology for atypical pathogens
Data were collected using REDCap™ (Research Electronic
Data Capture), an electronic data capture tool hosted on
the UT Health server. After study enrolment, participating
centers were allowed 7 days to complete electronic data
entry and confirm microbiological results.
Physicians taking care of CAP patients decided the
microbiological work-up according to local standard
operating procedures. Serology for atypical pathogens and
urinary antigen test for L. pneumophila were performed by
local hospital laboratories according to standard techniques.
Atypical pathogens were considered: M. pneumoniae, C.
pneumoniae, and L. pneumophila.
Study groups
Definition of CAP caused by atypical pathogens was
based on species-specific serology or urinary antigen posi-
tivity. Patients tested for atypical pathogens were defined as
having at least one of the following tests: urinary antigen
test for L. pneumophila, serology for L. Pneumophila, C.
pneumoniae, and M. pneumoniae.
Study definitions
CAP was deemed severe when patients were prescribed
one of the following interventions: intensive care unit
(ICU) admission, invasive or non-invasive mechanical
ventilation, or vasopressor/inotrope administration
during the first 24 h after hospital admission.
Definition of immunodepression was based on the diagno-
sis of ≥1of the following medical conditions in the six-month
period before hospital admission: hematological malignancy,
asplenia, aplastic anemia, neutropenia, long-term exposure
to biological drugs or steroids or chemotherapy or immuno-
suppressive therapy for hematological/solid organ transplant-
ation other than lung transplant, HIV/AIDS, and congenital
or genetic immunodepression. All site investigators were
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provided with a protocol including the above-mentioned
clinical definitions.
Statistical analysis
Testing frequency of atypical pathogens was calculated on
all CAP patients in the dataset. Prevalence of an atypical
pathogen was computed based on positive results of
serology and/or urinary antigen test for L. pneumophila
performed during the first 24 h of hospital stay. Categorical
variables, expressed as absolute frequencies and
percentages, were compared between groups using the
Chi-squared test. Regressions analyses were performed to
compare prevalence and compute odds ratios (OR) with
their 95% confidence interval (CI); furthermore, theywere
performed to assess the relationship between atypical
pathogen-related pneumonia and demographic, epidemio-
logical, and clinical variables. Circular relation analysis
using the Chi-squared test was performed to compare the
prevalence between countries and continents. Statistical
significance when P was < 0.05. All statistical analyses were
performed with IBM SPSS, Statistics for Mac, version 22.0,
and STATA 13. Prevalence maps were created using Stat
Planet software.
Results
Testing for atypical pathogens
A total of 3702 hospitalized CAP patients were recruited
in 54 countries across 6 continents. Among them, 1250
(33.8%) patients were tested for atypical pathogens: 1186
(32.0%) for L. pneumophila (either urinary antigen or
serology), 251 (6.8%) for M. pneumoniae (serology), and
228 (6.1%) for C. pneumoniae (serology). Distribution of
testing frequencies across countries is showed in Fig. 1a.
The frequency of patients tested for atypicals was signifi-
cantly higher in Europe in comparison with the rest of the
world (46.0% VS. 12.7%, P < 0.0001). The lowest testing
frequency was recorded in Africa and South America (5.8
and 5.0%, respectively). The highest frequencies of patients
tested for atypicals in countries enrolling > 100 CAP pa-
tients were detected in Spain (70.8%), Italy (63.8%), Portugal
(43.3%), Germany (23.1%), and USA (21.4%) (Table 1). Data
on testing for L. pneumophila, M. pneumoniae, and C.
pneumoniae are reported in the additional files (Add-
itional file 1: Table A). Detection of L. pneumophila urinary
antigen was the most prevalent test performed worldwide
(32.0%).
The frequencies of patients tested for atypical pathogens
were lower among those with severe CAP in comparison
with those with non-severe CAP (30.5% VS. 35.0% for atyp-
ical pathogens other than L. pneumophila, P = 0.009; 28.3%
VS. 33.5% for L. pneumophila, P = 0.003). L. pneumophila
testing was lower in ICU patients. Univariate analysis
comparing characteristics of tested and non-tested patients
is reported in Table 3, column A.
Prevalence of atypical pathogens
At least one atypical pathogen was isolated in 63 (4.7%)
patients out of those tested for atypicals. L. pneumophila
was detected in 30 (2.5%), M. pneumoniae in 26 (10.3%),
and C. pneumoniae in 8 (3.5%) patients. The prevalence
of atypical pathogens ranged from 0.0 to 36.4% and from
0.0 to 66.7% across different continents and countries,
see Fig. 1b. Italy showed the highest prevalence of atyp-
ical pathogens in comparison with the rest of the world
(7.5% VS. 4.2%, P = 0.022), whereas Spain showed the
lowest prevalence (2.2% VS. 6.5%, P = 0.001) (Table 2).
Patients with CAP caused by atypical pathogens were
significantly younger, showed less cardiovascular, renal,
and metabolic comorbidities in comparison with patients
with CAP caused by other pathogens CAP (Table 3,
column B and Table 4).
Discussion
This secondary analysis of the GLIMP database found that
only a third of patients hospitalized for CAP were tested
for atypical pathogens worldwide, with a large variability
among continents and countries. Patients with severe
CAP were less likely to be tested for all atypical pathogens.
Furthermore, L. pneumophila testing frequency was lower
in ICU patients. Among those tested for, the prevalence of
CAP caused by atypical pathogens was low. Younger age,
female gender, and having a less comorbidities (cardiovas-
cular disease, chronic renal failure) were factors associated
with CAP due to atypicals.
The most frequent test for atypical pathogens performed
in hospitalized patients with CAP was the Legionella
urinary antigen (32.0%), followed by Legionella serology,
whereas frequency of serological testing for any atypical
pathogens was very low (6.8 and 6.1% for M. pneumoniae
and C. pneumoniae, respectively).
However, information on molecular biology was not
retrieved in the GLIMP dataset based on missing recom-
mendations by international guidelines [1, 7]. Although
molecular techniques was found helpful in the diagnosis of
CAP caused by L. pneumophila, findings from different
studies showed that single available tests were not reliable
for the detection of M. pneumoniae and C. pneumoniae in
CAP patients [9–11]. In addition, molecular studies carried
out in large population groups found financial limitations
and lack of standardization [6, 12, 13]. Finally, these results
are intended to be a real-life snapshot of what it is really
done in different countries worldwide; we deem that it is
unrealistic a worldwide shift to PCR techniques considering
that data presented here suggest that even the most com-
mon and affordable test, the urinary antigen for Legionella,
is not routinely prescribed.
One of the major implications of a poor standardized
approach for atypical pathogen testing is the wide het-
erogeneity across continents and countries. In Europe,
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almost half of the patients in the GLIMP database was
investigated for atypical pathogens, thus resulting in the
highest testing frequency. However, among European
countries a significant variability was found. For ex-
ample, the testing frequency was higher in the Mediter-
ranean countries than in Northern Europe, ranging from
10.7% in United Kingdom to 70.8% in Spain. This signifi-
cant difference may be caused by several factors, includ-
ing the importance given to atypical pathogens in
relation with national epidemiological reports and the
lack of interest for this microbiological work-up in
countries where extensive empirical therapy is routinely
offered to patients. Interestingly, although large differ-
ences in frequencies of testing were found, prevalence of
atypical pathogens seems to be quite similar in Europe,
ranging from 1.6 to 6.5%, with the only exception of
Italy and Spain.
Furthermore, our data did not suggest significant clin-
ical differences between patients who underwent testing
for atypical pathogens and those who did not. The recent
guidelines for the management of CAP published by the
European Respiratory Society suggest a comprehensive
microbiological work-up in severe patients [1]. However,
we found that severe CAP was not a relevant driver for
testing. Same results were obtained for other severity indi-
cators, such as ICU admission, invasive/non-invasive
mechanical ventilation, and administration of vasopres-
sors. The low frequency testing may be explained by the
Fig. 1 a) Worldwide map on testing for atypical pathogens in hospitalized patients with community-acquired pneumonia (CAP) by country.
Denominator: all CAP for each country. b) Worldwide map on prevalence of atypical pathogens in community-acquired pneumonia (CAP) in
hospitalized patients by country. Denominator: all CAP tested for atypical pathogens for each country. Figure 1 is original and it was created
using Stat Planet software with the information created from the study
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recommendation of several guidelines on broad empirical
coverage in severe patients [1, 14–16]. Notably, despite
cost-effectiveness and ease of use of urinary antigen test,
L. pneumophila testing frequency was also lower in ICU
patients. These data are consistent with those showed by
Singanayagam who demonstrated that pneumonia severity
scores, such as PSI and CURB-65, are poor predictors of
microbial etiology and that atypical pathogens are more
prevalent in patients with less disease severity at their
presentation [17].
The present study showed that the estimated prevalence
of atypical pathogens in hospitalized CAP patients is low
during a non-epidemic season (i.e., from March to June).
The proportional distribution was heterogeneous and the
majority of the reported cases were from Europe. Inter-
continent differences suggest that prevalence is lower in
Africa and South America. L. pneumophila and M. pneu-
moniae seem to be the most frequent pathogens world-
wide. The prevalence of M. pneumoniae is highest in South
America, whereas L. pneumophila did show a homoge-
neous geographical distribution. L. pneumophila prevalence
was similar to that recorded by Viasus (5.4% among 3934
immunocompetent hospitalized CAP patients after a
15-year study) [18]. Conversely, our data might underesti-
mate the high incidence of legionellosis (12%) in the US
population as previously reported by Vergis [19].
The CAPO database reported on a prevalence for atypical
pathogens ranging from 20 to 28% across 21 countries over
a five-year period (epidemic seasons included) [6]. The
Authors performed a very comprehensive microbiological
work-up including PCR for atypicals for the majority of
CAP patients, but it is unclear the proportion of cases diag-
nosed by serological or molecular techniques. National and
regional epidemiological reports showed a prevalence ran-
ging from 9 to 50% [20–24]. Singanayagam and Coworkers
recently published a secondary analysis of four independent
prospective CAP datasets with atypical pathogens account-
ing for a global frequency of 14% in patients with identified
microbiological positivity [17]. Interestingly, most of these
Table 1 Testing frequency for atypical pathogens (all) in hospitalized patients with community-acquired pneumonia across different
continents and countries
Continent/Country Tested/Total (%) Rest of the world Tested/Total (%) P
Europe 1078/2344 (46%) 172/1358 (12.7%) < 0.0001
North America 105/529 (19.8%) 1145/3173 (36.1%) < 0.0001
Asia 44/415 (10.6%) 1206/3287 (36.7%) < 0.0001
Oceania 3/40 (7.5%) 1247/3662 (34.1%) < 0.0001
Africa 9/156 (5.8%) 1241/3546 (35%) < 0.0001
South America 11/218 (5%) 1239/3484 (35.6%) < 0.0001
Spain 455/643 (70.8%) 795/3059 (26%) < 0.0001
Italy 293/459 (63.8%) 957/3243 (29.5%) < 0.0001
Greece 54/87 (62.1%) 1196/3615 (33.1%) < 0.0001
France 40/66 (60.6%) 1210/3636 (33.3%) < 0.0001
Portugal 58/134 (43.3%) 1192/3568 (33.4%) 0.018
Bulgaria 21/51 (41.2%) 1229/3651 (33.7%) 0.260
Denmark 26/89 (29.2%) 1224/3613 (33.9%) 0.358
Germany 40/173 (23.1%) 1210/3529 (34.3%) 0.002
US 102/477 (21.4%) 1148/3225 (35.6%) < 0.0001
Serbia 10/56 (17.9%) 1240/3646 (34%) 0.011
Croatia 16/103 (15.5%) 1234/3599 (34.3%) < 0.0001
UK 20/186 (10.8%) 1230/3516 (35%) < 0.0001
Argentina 11/190 (5.8%) 1239/3512 (35.3%) < 0.0001
Pakistan 6/109 (5.5%) 1244/3593 (34.6%) < 0.0001
Table 2 Prevalence of atypical pathogens in hospitalized
patients with community-acquired pneumonia across different
continents
Continent Tested/Total (%) Rest of the world
Tested/Total (%)
P
Africa 2/9 (22.2%) 60/1241 (4.8%) 0.070
Asia 2/44 (4.5%) 60/1206 (5%) 1
Europe 50/1078 (4.6%) 12/172 (7%) 0.091
North America 6/105 (5.7%) 56/1145 (4.9%) 0.922
Oceania 0/3 (0%) 62/1247 (5%) 1
South America 5/11 (45%) 57/1239 (4.6%) 0.001
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Table 3 Clinical characteristics of tested and non-tested patients for both all atypical pathogens and L. pneumophila (column A)
and of patients with community-acquired pneumonia caused and not caused by atypical pathogen (column B)






CAP (N = 63)
Non-atypical pathogen
CAP (N = 1187)
P
Demographic characteristics
Age, years 68 (46–75) 70 (51–81) 0.43 62 (43–72) 71 (56–81) 0.015
Male, n (%) 714 (57) 1459 (59) 0.83 27 (43) 687 (58) 0.027
Underweight, n (%) 56 (4.5) 110 (4.5) 0.36 3 (4.8) 53 (4.5) 1
Obesity, n (%) 208 (16.6) 369 (15) 0.21 11 (17.4) 197 (16.6) 0.811
Respiratory past medical history
Active lung cancer, s (%) 27 (2.2) 82 (3.3) 0.50 0 (0) 27 (2.3) 0.64
Asthma, n (%) 85 (6.8) 176 (7.2) 0.73 3 (4.8) 82 (6.9) 0.79
Bronchiectasis, n (%) 61 (4.9) 117 (4.6) 0.87 1 (1.6) 60 (5) 0.36
Chronic aspiration, n (%) 71 (5.7) 186 (7.6) 0.03 0 (0) 71 (6) 0.45
COPD, n (%) 327 (26.2) 609 (24.8) 0.38 14 (22.2) 313 (26.3) 0.51
FEV1≤ 30%, n (%) 27 (2.2) 73 (3) 0.16 0 (0) 27 (2.2) 0.64
Current/former smoker, n (%) 427 (34.2) 818 (33.4) 0.63 18 (28.5) 409 (34.4) 0.382
Interstitial lung disease, n (%) 34 (2.7) 61 (2.5) 0.66 1 (1.6) 33 (2.8) 1
Obstructive sleep apnea, n (%) 51 (4.1) 79 (3.2) 0.19 0 (0) 51 (4.3) 0.17
Oxygen therapy at home, n (%) 83 (6.6) 141 (5.7) 0.30 4 (6.4) 79 (6.6) 1
Lung transplantation, n (%) 1 (0.8) 6 (0.2) 0.44 0 (0) 1 (0.8) 1
Tracheostomy, n (%) 15 (1) 38 (1.5) 0.45 0 (0) 15 (1.3) 1
Cardiovascular past medical history
Arrhythmia, n (%) 218 (17.4) 309 (12.6) < 0.001 11 (17.7) 207 (17.4) 0.947
Coronary artery disease, n (%) 178 (14.2) 345 (14.1) 0.88 3 (4.8) 175 (14.7) 0.030
Heart failure, n (%) 88 (7) 210 (8.2) 0.26 2 (3.2) 86 (7.2) 0.312
Hypertension, n (%) 183 (14.6) 323 (13) 0.14 4 (6.5) 179 (14.4) 0.790
Chronic medications
Inhaled corticosteroids use, n (%) 207 (16.6) 383 (15.6) 0.47 4 (6.5) 203 (17.1) 0.028
Proton Pump Inhibitor use, n (%) 401 (32) 627 (25.6) < 0.001 17 (27.4) 384 (32.3) 0.423
Statins use, n (%) 285 (22.8) 470 (19.2) 0.011 9 (14.5) 276 (23.2) 0.111
Steroids use, n (%) 86 (6.8) 208 (8.5) 0.09 4 (6.5) 82 (6.9) 1
Chronic interventions
Enteric tube feeding, n (%) 11 (0.88) 41 (1.7) 0.05 0 (0) 11 (1) 1
Haemodialysis, n (%) 12 (1) 40 (1.6) 0.11 0 (0) 12 (1) 1
Indwelling catheter, n (%) 18 (1.4) 61 (2.5) 0.04 2 (3.2) 16 (1.4) 0.22
Immunosuppressive conditions
Active solid tumour, n (%) 88 (7) 199 (8.1) 0.27 1 (1.6) 87 (7.3) 0.12
HIV infection, n (%) 28 (2.24) 95 (3.9) 0.009 2 (3.2) 26 (2.2) 0.64
AIDS, n (%) 15 (1.2) 50 (2) 0.08 2 (3.2) 13 (1.1) 0.16
Aplastic anaemia, n (%) 6 (0.3) 8 (0.3) 0.57 0 (0) 6 (0.5) 1
Asplenia, n (%) 6 (0.3) 6 (0.2) 0.24 0 (0) 6 (0.5) 1
Biological drug use, n (%) 14 (1.1) 23 (0.9) 0.60 0 (0) 14 (1.2) 1
Chemotherapy in the last 3 months, n (%) 48 (3.8) 97 (3.8) 0.92 1 (1.6) 47 (4) 0.51
Haematological malignancy, n (%) 73 (5.8) 89 (3.6) =0.003 2 (3.2) 71 (6) 0.57
Immunocompromised patients, n (%) 230 (18.4) 435 (17.7) 0.62 12 (19.4) 218 (18.4) 0.84
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studies suggested that atypical pathogens are more relevant
in the outpatient population [17, 20–24].
The prevalence estimates on atypical microorganisms
might be limited. Even if the combination of serology and
molecular techniques was suggested to increase sensitivity,
diagnostic tools only accounted on serology for atypical
pathogens and urinary antigen for Legionella [1, 25]. Then,
prevalence estimation can depend on frequency and
comprehensiveness of the microbiological work-up.
Second, since patients have been enrolled on a single
day in the months of March, April and May, most of
data come from non-epidemic season in northern
hemisphere, thus biasing a plausible estimation of atyp-
ical pathogen epidemiology.
However, the low testing frequency underscores the poor
emphasis given by physicians or local health authorities to
the role of atypicals. Therefore, the controversy on empiric
coverage for atypical pathogens should be addressed after a
more adequate description of the epidemiological burden
and a sensitization of attending physicians.
Potential risk factors for atypical pathogens were also
investigated. In this analysis cardiovascular disease as
well as chronic renal failure act as protective factors for
atypical etiology. Our understanding is that these results
Table 3 Clinical characteristics of tested and non-tested patients for both all atypical pathogens and L. pneumophila (column A)
and of patients with community-acquired pneumonia caused and not caused by atypical pathogen (column B) (Continued)






CAP (N = 63)
Non-atypical pathogen
CAP (N = 1187)
P
Neutropenia, n (%) 13 (1.8) 35 (1.4) 0.36 0 (0) 13 (1.1) 1
Other chronic medical conditions
Chronic renal failure, n (%) 144 (11.5) 256 (10.4) 0.31 2 (3.2) 142 (12) 0.036
Dementia, n (%) 136 (18.9) 272 (11.1) 0.87 5 (8.1) 131 (11) 0.46
Diabetes mellitus, n (%) 266 (21.3) 516 (21) 0.86 7 (11.3) 259 (21.8) 0.049
Liver disease, n (%) 59 (4.72) 81 (3.03) 0.36 4 (6.5) 55 (4.6) 0.53
Malnutrition, n (%) 95 (7.6) 0 (0) 0.08 4 (6.5) 91 (7.7) 1
Mental illness, n (%) 83 (6.6) 0 (0) 0.73 4 (6.5) 79 (6.6) 1
Prosthetic material, n (%) 41 (3.3) 75 (3) 0.76 1 (1.6) 40 (3.4) 0.71
Recurrent skin infections, n (%) 14 (1.1) 44 (1.8) 0.13 1 (1.6) 13 (1.1) 0.51
Other non-medical conditions
Bedridden, n (%) 110 (8.8) 305 (12.4) 0.001 3 (4.8) 86 (7.2) 0.61
Contact sport, n (%) 1 (0.1) 5 0.67 0 (0) 1 (1) 1.0
Healthcare worker, n (%) 20 (1.6) 27 (1.1) 0.21 5 (7.9) 15 (1.3) 0.002
Homeless, n (%) 12 (1.8) 23 (0.9) 1.0 0 (0) 12 (1) 1
Living in crowded conditions, n (%) 236 (18.9) 485 (19.8) 0.54 0 (0) 9 (0.8) 1
Nursing home resident, n (%) 86 (6.88) 216 (8.8) 0.042 11 (17.7) 225 (18.9) 0.81
Chronic aspiration, n (%) 71 (5.7) 186 (7.6) 0.034 0 (0) 62 (5.3) 0.047
Previous infections/colonization
Prior mycobacterial diseases, n (%) 31 (2.5) 65 (2.6) 0.82 3 (4.8) 28 (2.4) 0.19
Prior MRSA infection/colonisation, n (%) 30 (2.4) 56 (2.3) 0.82 0 (0) 30 (2.5) 0.39
Prior ESBL-producing bacterial infection, n (%) 21 (1.7) 34 (1.4) 0.48 1 (1.6) 20 (1.7) 1
Prior Pseudomonas spp. infection, n (%) 30 (2.4) 71 (2.9) 0.45 1 (1.6) 29 (2.4) 1
Current pneumonia episode
Severe CAP, n (%) 314 (25.1) 716 (29.2) 0.009 21 (33) 293 (24.7) 0.103
ICU or HDU admission, n (%) 277 (22.2) 619 (25.2) =0.039 18 (28) 259 (22) 0.181
Either invasive or non-invasive ventilation, n (%) 206 (16.5) 456 (17.9) 0.11 12 (19) 194 (16.3) 0.531
Invasive ventilation, n (%) 114 (9.1) 240 (9.4) 0.55 3 (4.8) 111 (9.3) 0.230
Non-invasive ventilation, n (%) 118 (9.4) 231 (9) 1 9 (14.3) 109 (9.1) 0.161
CAP; Community-acquired pneumonia, MRSA; Methicillin resistant Staphylococcus aureus, COPD; Chronic obstructive pulmonary disease, FEV1; Forced expiratory volume
during the first second, CAD; Coronary artery disease, ESBL; extended-spectrum beta-lactamases, LRTI; lower respiratory tract infections
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might be a function of age, being patients with atypical
pneumonia younger than others.
Conclusions
In conclusion, this real-life study demonstrates that test-
ing for atypical pathogens in hospitalized patients with
CAP is not routinely performed worldwide.
Testing for atypical pathogens is poorly standardized
and a wide inter-country heterogeneity was found. Testing
rates could not appropriately describe prevalence of atypi-
cals in different settings. Further studies are needed to bet-
ter assess the epidemiological burden and the utility of the
current microbiological and clinical recommendations.
Additional file
Additional file 1: Table A: Tables with testing frequencies for specific
atypical pathogens across continents (A1: Testing frequencies for C.
pneumoniae across continents; A2: Testing frequencies for M. pneumoniae
across continents; A3: Testing frequencies for L. pneumophila across
continents).- Brief description of the data: a table in three parts reporting
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